SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 6th, 2019 • GT Biopharma, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of February 4, 2019, between GT Biopharma, Inc., a Delaware corporation and includes any successor Company thereto (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and permitted assigns, a “Purchaser” and collectively, the “Purchasers”).
SECURED CONVERTIBLE NOTE DUE AUGUST 2, 2019GT Biopharma, Inc. • February 6th, 2019 • Pharmaceutical preparations • New York
THIS CONVERTIBLE NOTE is one of a series of duly authorized and validly issued Notes of GT BIOPHARMA, INC., a Delaware corporation, (the “Borrower”), having its principal place of business at 310 N. Westlake Blvd, Suite 206, Westlake Village, CA 91362, due August 2, 2019 (this note, the “Note” and, collectively with the other notes of such series, the “Notes”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • February 6th, 2019 • GT Biopharma, Inc. • Pharmaceutical preparations • New York
REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of February 4, 2019, by and among GT Biopharma, Inc., a Delaware corporation, with headquarters located at 310 N. Westlake Blvd, Suite 206, Westlake Village, CA 91362 (the "Company"), and the investors listed on the Schedule of Purchasers attached hereto (each, a "Purchaser" and collectively, the "Purchasers").
SECURITY AGREEMENTSecurity Agreement • February 6th, 2019 • GT Biopharma, Inc. • Pharmaceutical preparations • New York
This SECURITY AGREEMENT, dated as of February 4, 2019 (this “Agreement”), is among GT Biopharma, Inc., a Delaware corporation (the “Company”), certain Subsidiaries of the Company which shall become a party to this Agreement by execution and delivery of the form annexed hereto as Annex A and the Subsidiary Guaranty annexed thereto (each such Subsidiary, a “Guarantor” and together with the Company, the “Debtors”) Alpha Capital Anstalt, as collateral agent (the “Collateral Agent”) for the holders of the Company’s 10% senior Convertible Debentures issued on August 2, 2018, September 7, 2018 and September 24, 2018 as disclosed on Schedule 1 annexed hereto in the original principal amount of $9,058,962 and the Secured Convertible Notes issued at or about February 4, 2019 in the original aggregate principal amount of $1,352,224, and such other of the Company’s Secured Convertible Notes which may be issued in the future pursuant to a Securities Purchase Agreement among the Company and the purc
